BeiGene is a commercial-stage biopharmaceutical company rooted in China that is dedicated to becoming a global leader in the discovery, development and commercialization of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.
We have three internally-developed late-stage clinical drug candidates:
- Zanubrutinib (BGB-3111) — an investig...
|Stock Quote||more >|
06/18/18 4:00 p.m. ET
Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.
|Recent Press Releases||more >|
|BeiGene Provides Development Update and Presents Clinical Data on Zanubrutinib at the 23rd Congress of the European Hematology Association - June 15, 2018|
|Investor Call Scheduled Today, June 15, 2018, at 8:00 am EDT CAMBRIDGE, Mass. and BEIJING, China, June 15, 2018 (GLOB... Read More|
|BeiGene to Present at the Goldman Sachs 39th Annual Global Healthcare Conference - June 6, 2018|
|CAMBRIDGE, Mass., and BEIJING, China, June 06, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stag... Read More|